SYNLAB acquires Sistemas Genmicos from the Ascires group in Spain, strengthening its European leadership in genetics

DGAP-News: SYNLAB AG / Keyword(s): Acquisition

SYNLAB acquires Sistemas Genómicos from the Ascires group in Spain, strengthening its European leadership in genetics

07.01.2022 / 08:00
The issuer is solely responsible for the content of this announcement.

– Sistemas Genómicos’ strong expertise in genetics – including bioinformatics, sequencing, molecular biology and molecular genetics – will strategically complement SYNLAB’s already leading genetic services offering and expand SYNLAB’s leadership in specialist testing in Europe

– The integration of more than 100 highly qualified professionals with in-depth knowledge of technology and big data will strengthen SYNLAB’s innovation power and strategic positioning in Spain and beyond

SYNLAB, Europe’s leading provider of medical diagnostic services, today announced the acquisition of Valencia-based Sistemas Genómicos from Ascires Group, a laboratory specializing in genetics and bioinformatics. The acquisition will strengthen and complement SYNLAB’s expertise and capabilities in genetics and accelerate the digital transformation of its diagnostic services offering.

With an expected turnover of around 20 million euros[1] in 2021, Sistemas Genómicos is a key player in the Spanish diagnostics market. The laboratory has a strong background in genetic sequencing as well as molecular biology and genetics, with more than 20 years of experience and more than 100 highly qualified experts. More than that, the lab’s substantial expertise in bioinformatics – the software-assisted analysis of biological data – makes it a forerunner in the digital transformation of diagnostics.

Mathieu Floreani, CEO of SYNLAB Group, underlines the strategic value of this acquisition: “With regard to the diagnostics market, genetic testing and counseling as well as the digitization and automation of diagnostic services hold vast potential for growth in the future. Sistemas Genómicos is the only laboratory internationally certified to provide genetic analysis and diagnostic services throughout the human life cycle, and a leader in bioinformatics, they will thus perfectly enrich and complete the SYNLAB network. new colleagues, exchanging knowledge and pursuing our path of growth together.”

CEO of Ascires Grupo Biomédico, Lorena Saus, highlights Ascires’ strategic logic of focusing on precision medicine integrated into clinical and health activities: “Ascires continues to focus on the integration of genomic data with clinical information from diagnostic imaging and nuclear medicine, an essential activity of the group for more than 50 years. Thanks to an extraordinary precision acquired thanks to our long-standing expertise, Ascires has become a reference organization in the specialties fields such as neurology and cardiology. There is no doubt that the integration of Sistemas Genómicos into the SYNLAB network will be a catalyst for both companies and their excellent professionals”.

The acquisition of Sistemas Genómicos is part of SYNLAB’s ambitious M&A strategy. The company continues its acquisitions focused on creating synergies, expanding its network of laboratories and increasing its technological capacity, allowing it to complement its services as well as its client base of patients and customers. SYNLAB expects to spend more than €200 million on mergers and acquisitions in 2022.

For more information:


SYNLAB, (ISIN: DE000A2TSL71, SYMBOL: SYAB) is Europe’s largest clinical laboratory services and medical diagnostics company and provides a full range of innovative and reliable medical diagnostics for patients, practicing physicians, clinics and medical professionals. ‘pharmaceutical industry.

– Offering the best level of service in the industry, SYNLAB is the partner of choice for diagnostics in human and veterinary medicine. The Group is constantly innovating in medical diagnostic services for the benefit of patients and customers.

– SYNLAB operates in 36 countries on four continents and holds leading positions in most markets. More than 20,000 employees, including more than 1,200 medical experts, as well as a large number of other specialists such as biologists, chemists and laboratory technicians, contribute every day to the worldwide success of the Group. SYNLAB performs ~500 million laboratory tests per year and achieved a turnover of 2.6 billion euros in 2020.

– More information can be found at [1] Including diagnosis of SARS-CoV-2

07.01.2022 Broadcast of a Corporate News, transmitted by the DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP distribution services include regulatory announcements, financial/corporate news and press releases.
Archive at